Výsledky vyhledávání

Akademický článek

Should they wait? Two children under 3 years old infected by HCV 1b successfully treated by ledipasvir/sofosbuvir: A report of two cases

Autor: Mingna Li, Kuerbannisa Wulayin, Shutao Lin, Chao Wu, Lubiao Chen

Publikováno v: Liver Research, Vol 7, Iss 4, Pp 361-364 (2023)

Although direct-acting antivirals (DAAs) have notably increased the sustained virological response (SVR) rates in hepatitis C virus (HCV)-infected adolescent patients, the efficacy and safety for young children under 3 years old remain unclear. Curre

Externí odkaz: https://doaj.org/article/6c43d2c02ba243b2967b3743565edd83

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world

Autor: Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak

Publikováno v: The Korean Journal of Internal Medicine, Vol 34, Iss 4, Pp 794-801 (2019)

Background/Aims Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safet

Externí odkaz: https://doaj.org/article/88f6f18709e942788fb1a3b900ac490e

Zobrazit plný text záznamu

Akademický článek

Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety

Autor: Hye Won Lee, Se Rim Oh, Dong Yun Kim, Yechan Jeong, Seungtaek Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park

Publikováno v: Gut and Liver, Vol 12, Iss 3, Pp 324-330 (2018)

Background/AimsThe treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection. We investigated the real-world efficacy, changes in liver stiffness a

Externí odkaz: https://doaj.org/article/71f698da40ac4af1a6b89a414ca2312a

Zobrazit plný text záznamu

Akademický článek

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients

Autor: Shinya Taki, Hideyuki Tamai, Yoshiyuki Ida, Naoki Shingaki, Akira Kawashima, Ryo Shimizu, Kosaku Moribata, Takao Maekita, Mikitaka Iguchi, Jun Kato, Taisei Nakao, Masayuki Kitano

Publikováno v: Gut and Liver, Vol 12, Iss 1, Pp 86-93 (2018)

Background/AimsAlthough daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy o

Externí odkaz: https://doaj.org/article/6f0cf7ae9d7b412d8184b90021df8600

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Role of host and viral factors and genetic variation of IL28B on therapy outcome in patients with chronic hepatitis C genotype 1b from Serbia

Autor: Snežana Jovanović-Ćupić, Nina Petrović, Milena Krajnović, Maja Bundalo, Nikola Kokanov, Ana Božović, Gorana Stamenković

Publikováno v: Genetics & Applications, Vol 3, Iss 1 (2019)

In hepatitis C virus (HCV) infection viral and host factors can influence therapy outcome to pegylated interferon/ribavirin (PEG-IFN/RBV) and progression of liver fibrosis. Although novel direct-acting antivirals (DAAs) show newly successful treatmen

Externí odkaz: https://doaj.org/article/6cb379ff925f44cb8cf90cc2f4b7471b

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání